Slide 1: Novocure (NVCR) Overview updated March 1, 2016
Novocure (NVCR) Overview updated March 1, 2016 Actor Portrayal
Slide 2: Notice
Notice This presentation contains certain forward-looking statements with respect to the business of Novocure and certain of its plans and objectives, including with respect to the development and commercialization of its lead product candidate, Optune, for a number of oncology indications. These fo
Slide 3: Tumor Treating Fields
Tumor Treating Fields Novel, anti-mitotic solid tumor cancer therapy Surgery Radiation Pharmacological Treatments Tumor Treating Fields Most frequently employed therapy Reduces size of a tumor prior to initiation of additional therapies Kills cells when delivered at high doses Injures healthy tissue
Slide 4: Frequency Tuned to Specific Cell Types
Frequency Tuned to Specific Cell Types Treatment does not harm normal cell growth © Novocure 2016
Slide 5: Non-invasive, Portable Delivery
Non-invasive, Portable Delivery Battery or wall-powered electric field generator Single-use transducer arrays replaced 2-3 times a week © Novocure 2016
Slide 6: Home Use, Quality of Life Maintained
Home Use, Quality of Life Maintained Should be used at least 18 hours a day Mild side-effect profile with no known systemic toxicity Actor Portrayal © Novocure 2016
Slide 7: Second Generation Optune System
Second Generation Optune System Half the size and weight of the first generation – only 2.7 pounds CE marked and available in Europe PMA supplement filed with FDA in December 2015 (180-day review) © Novocure 2016
Slide 8: Extensive Preclinical Research
Extensive Preclinical Research 15+ years of research and multiple peer-reviewed publications Deep understanding of the underlying mechanism © Novocure 2016
Slide 9: Initial FDA Approval in 2011
Initial FDA Approval in 2011 Monotherapy treatment for recurrent GBM Optune (n=120) Chemotherapy (n=117) Median OS, months 6.6 6.0 HR and p value HR=0.86, p=0.27 4-year survival 8% 0% FDA Approved Summary of Safety and Effectiveness Data “…NovoTTF-100A treatment exhibits minimal toxicity, clinically
Slide 10: EF-14 Phase Trial Initiated in 2009
EF-14 Phase 3 Trial Initiated in 2009 Combination Therapy for Newly Diagnosed GBM A prospective, multicenter trial of TTFields together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM 80 centers; 695 newly diagnosed GBM patients randomized 2:1 (TTFields plus TMZ
Slide 11: EF-14 Progression Free Survival
EF-14 Progression Free Survival Intent-to-treat Population TTFields + TMZ (n=210) TMZ alone (n=105) Median PFS, months 7.2 4.0 HR and p value HR=0.62, p=0.001 © Novocure 2016
Slide 12: EF-14 Overall Survival
EF-14 Overall Survival As-treated Population TTFields + TMZ (n=196) TMZ alone (n=84) Median OS, months 20.5 15.6 HR and p value HR=0.66, p=0.004 2-year survival 48% 32% p value p=0.0058 © Novocure 2016
Slide 13: FDA Approval on October 5, 2015
FDA Approval on October 5, 2015 Combination treatment for newly diagnosed GBM © Novocure 2016
Slide 14: Established Commercial Organization
Established Commercial Organization Recurrent GBM patients primarily treated in academic hospitals; early commercial efforts focused on neuro oncologists at academic centers Estimate 60% of newly diagnosed GBM treated in community setting U.S. sales team expanded in 2015 to reach community-based pra
Slide 15: Direct to Patient Distribution Model
Direct to Patient Distribution Model Physician sends prescription order to Novocure Physician or Novocure uses NovoTAL System to create array placement map Novocure delivers Optune to home and trains patient/family Novocure provides 24/7 tech support and supplies transducer arrays Novocure bills thi
Slide 16: Established Reimbursement History
Established Reimbursement History Nine U.S. payers have positive coverage covering >107 million people Have secured coverage for approximately 98% of U.S. patients with commercial and privately-administered government plans Appealing Medicare fee-for-service denials (20-25% of US patients) Pursuing
Slide 17: Novocure's Key Operating Statistics
Novocure’s Key Operating Statistics Prescriptions - leading indicator of demand (counted only once per patient) Conversion to new patients driven by fill rate and time to fill 73% fill rate in 2015 Relationship between filled prescriptions and active patients driven by duration of therapy Treatment
Slide 18: Significant QoQ Active Patient Growth
Significant QoQ Active Patient Growth Active patients drive revenues > 360% growth Nov. 2014 EF-14 presentation Global active patients at period end Oct. 2015 FDA approval U.S. certified centers U.S. sales colleagues 154 14 244 31 215 27 >190 17 >175 >300 © Novocure 2016
Slide 19: Selected Financial Data
Selected Financial Data Per U.S. GAAP, revenue is recognized when cash is collected Cost of revenues reflects costs incurred for patients on Optune in the period © Novocure 2016
Slide 20: Total Addressable GBM Market >$2.5B
Total Addressable GBM Market >$2.5B United States 12,500 GBM incidence 9,300 medically eligible for treatment $1.2 Billion TAM Target EU Markets 13,500 GBM incidence 10,000 medically eligible for treatment $1.3 Billion TAM Japan 1,500 GBM incidence 1,100 medically eligible for treatment $139 Million
Slide 21: Broad Applicability to Solid Tumors
Broad Applicability to Solid Tumors © Novocure 2016
Slide 22: Multiple Ongoing Clinical Trials
Multiple Ongoing Clinical Trials © Novocure 2016
Slide 23: Phase EF-15 Trial Non-small cell lung cancer
Phase 2 EF-15 Trial Non-small cell lung cancer Open label study (n=41) of TTFields at 150 kHz in combination with pemetrexed for advance non-small cell lung cancer Trial results published in Lung Cancer1 in July 2013 Efficacy endpoints TTFields with pemetrexed Pemetrexed-alone historical control2 Me
Slide 24: Phase PANOVA Trial Pancreatic cancer
Phase 2 PANOVA Trial Pancreatic cancer Open label study (n=20) of TTFields at 150 kHz with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma Second cohort (n=20) of TTFields at 150 kHz with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adenocarc
Slide 25: Anticipated 2016 Milestones
Anticipated 2016 Milestones NCCN guidelines update Increase positive coverage policies of Optune Phase 2 pilot PANOVA trial 2nd cohort last patient in Phase 3 pivotal METIS trial first patient in Phase 3 pivotal LUNAR trial first patient in FDA approval of second generation device Newly diagnosed GB